What question did this study set out to answer?

To evaluate the safety of COVID-19 vaccines during the first month of deployment in the U.S.

First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021

View Full Paper

Ask AI

Bookmark

Authors

Safety monitoring reveals common symptoms and low rates of serious adverse events after COVID-19 vaccination in the U.S.

To evaluate the safety of COVID-19 vaccines during the first month of deployment in the U.S.
Monitored symptoms reported to VAERS, including case reports of adverse events and deaths.
Analyzed data from v-safe system to track post-vaccination reactions.
Collected information from medical records and health care providers on reported deaths.
Headache (22.4%), fatigue (16.5%), and dizziness (16.5%) were the most common symptoms reported.
113 deaths were reported to VAERS, with no causal relationship established between vaccination and death.
Rare anaphylaxis occurred in 4.5 cases per million doses, primarily following second vaccine doses.

Gee et al. (2021) studied this question.

View Full Paper

Ask AI

Bookmark